Today’s formulation challenges are as diverse as they are demanding – from increasingly insoluble new chemical entities (NCEs) to highly bitter drugs, to increased regulatory emphasis on patient acceptance – arriving at a final dosage form that has commercial potential is a more complex proposition than ever.
Insighthub
Sponsored by:
